Cargando…

A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma

Osteosarcoma is the most common malignant bone tumor, and although there has been significant progress in its management, metastases often herald incurable disease. Here we defined genes differentially expressed between primary and metastatic osteosarcoma as metastasis-related genes (MRGs) and used...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Di, Xia, Kezhou, Yu, Ling, Gong, Changtian, Shi, Yubo, Li, Wei, Qiu, Yonglong, Yang, Jian, Guo, Weichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343004/
https://www.ncbi.nlm.nih.gov/pubmed/34368151
http://dx.doi.org/10.3389/fcell.2021.699212
_version_ 1783734184973434880
author Zheng, Di
Xia, Kezhou
Yu, Ling
Gong, Changtian
Shi, Yubo
Li, Wei
Qiu, Yonglong
Yang, Jian
Guo, Weichun
author_facet Zheng, Di
Xia, Kezhou
Yu, Ling
Gong, Changtian
Shi, Yubo
Li, Wei
Qiu, Yonglong
Yang, Jian
Guo, Weichun
author_sort Zheng, Di
collection PubMed
description Osteosarcoma is the most common malignant bone tumor, and although there has been significant progress in its management, metastases often herald incurable disease. Here we defined genes differentially expressed between primary and metastatic osteosarcoma as metastasis-related genes (MRGs) and used them to construct a novel six-MRG prognostic signature for overall survival of patients with osteosarcoma. Validation in internal and external datasets confirmed satisfactory accuracy and generalizability of the prognostic model, and a nomogram based on the signature and clinical variables was constructed to aid clinical decision-making. Of the six MRGs, FHIT is a well-documented tumor suppressor gene that is poorly defined in osteosarcoma. Consistent with tumor suppressor function, FHIT was downregulated in osteosarcoma cells and human osteosarcoma samples. FHIT overexpression inhibited osteosarcoma proliferation, migration, and invasion both in vitro and in vivo. Mechanistically, FHIT overexpression upregulate the epithelial marker E-cadherin while repressing the mesenchymal markers N-cadherin and vimentin. Our six-MRG signature represents a novel and clinically useful prognostic biomarker for patients with osteosarcoma, and FHIT might represent a therapeutic target by reversing epithelial to mesenchymal transition.
format Online
Article
Text
id pubmed-8343004
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83430042021-08-07 A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma Zheng, Di Xia, Kezhou Yu, Ling Gong, Changtian Shi, Yubo Li, Wei Qiu, Yonglong Yang, Jian Guo, Weichun Front Cell Dev Biol Cell and Developmental Biology Osteosarcoma is the most common malignant bone tumor, and although there has been significant progress in its management, metastases often herald incurable disease. Here we defined genes differentially expressed between primary and metastatic osteosarcoma as metastasis-related genes (MRGs) and used them to construct a novel six-MRG prognostic signature for overall survival of patients with osteosarcoma. Validation in internal and external datasets confirmed satisfactory accuracy and generalizability of the prognostic model, and a nomogram based on the signature and clinical variables was constructed to aid clinical decision-making. Of the six MRGs, FHIT is a well-documented tumor suppressor gene that is poorly defined in osteosarcoma. Consistent with tumor suppressor function, FHIT was downregulated in osteosarcoma cells and human osteosarcoma samples. FHIT overexpression inhibited osteosarcoma proliferation, migration, and invasion both in vitro and in vivo. Mechanistically, FHIT overexpression upregulate the epithelial marker E-cadherin while repressing the mesenchymal markers N-cadherin and vimentin. Our six-MRG signature represents a novel and clinically useful prognostic biomarker for patients with osteosarcoma, and FHIT might represent a therapeutic target by reversing epithelial to mesenchymal transition. Frontiers Media S.A. 2021-07-23 /pmc/articles/PMC8343004/ /pubmed/34368151 http://dx.doi.org/10.3389/fcell.2021.699212 Text en Copyright © 2021 Zheng, Xia, Yu, Gong, Shi, Li, Qiu, Yang and Guo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Zheng, Di
Xia, Kezhou
Yu, Ling
Gong, Changtian
Shi, Yubo
Li, Wei
Qiu, Yonglong
Yang, Jian
Guo, Weichun
A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma
title A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma
title_full A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma
title_fullStr A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma
title_full_unstemmed A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma
title_short A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma
title_sort novel six metastasis-related prognostic gene signature for patients with osteosarcoma
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343004/
https://www.ncbi.nlm.nih.gov/pubmed/34368151
http://dx.doi.org/10.3389/fcell.2021.699212
work_keys_str_mv AT zhengdi anovelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma
AT xiakezhou anovelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma
AT yuling anovelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma
AT gongchangtian anovelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma
AT shiyubo anovelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma
AT liwei anovelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma
AT qiuyonglong anovelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma
AT yangjian anovelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma
AT guoweichun anovelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma
AT zhengdi novelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma
AT xiakezhou novelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma
AT yuling novelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma
AT gongchangtian novelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma
AT shiyubo novelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma
AT liwei novelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma
AT qiuyonglong novelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma
AT yangjian novelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma
AT guoweichun novelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma